CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring
Source: NLP:warfarin
Methoxsalen Interactions
Brand names: Uvadex
Photoactivated Radical Generator · Psoralen · Photoabsorption
Route: Extracorporeal
FDA Black Box Warning
UVADEX ® (methoxsalen) Sterile Solution should be used only by physicians who have special competence in the diagnosis and treatment of cutaneous T-cell lymphoma and who have special training and experience in the THERAKOS ® CELLEX ® Photopheresis System. Please consult the CELLEX ® Operator's Manual before using this product.
Contraindications
CONTRAINDICATIONS UVADEX ® (methoxsalen) Sterile Solution is contraindicated in patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, other psoralen compounds or any of the excipients. Patients possessing a specific history of a light sensitive disease state should not initiate methoxsalen therapy. Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum and albinism. UVADEX ® Sterile Solution is contraindicated in patients with aphakia, because of the significantly increased risk of retinal damage due to the absence of lenses. Patients should not receive UVADEX ® if they have any contraindications to the photopheresis procedure.
Pregnancy & Breastfeeding
Pregnancy Methoxsalen may cause fetal harm when given to a pregnant woman. Doses of 80 to 160 mg/kg/day given during organogenesis caused significant fetal toxicity in rats. The lowest of these doses, 80 mg/kg/day, is over 4000 times greater than a single dose of UVADEX ® on a mg/m 2 basis. Fetal toxicity was associated with significant maternal weight loss, anorexia and increased relative liver weight. Signs of fetal toxicity included increased fetal mortality, increased resorptions, late fetal death, fewer fetuses per litter, and decreased fetal weight. Methoxsalen caused an increase in skeletal malformation and variations at doses of 80 mg/kg/day and above. There are no adequate and well-controlled studies of methoxsalen in pregnant women. If UVADEX ® is used during pregnancy, or if the patient becomes pregnant while receiving UVADEX ® , the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
3 interactions on record
CYP1A2 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.
Source: NLP:warfarin sodium
Methoxsalen + RiluzoleModerate
CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.
Source: NLP:riluzole